DSM265

Takeda

Product vision
  • Part of a single-exposure radical cure

  • Potential for chemoprotection

MoA
  • Plasmodial dihydroorotate dehydrogenase (DHODH) inhibitor

Key features
  • Novel mechanism of action

  • 400mg human dose gives concentrations above Minimal Parasiticidal Concentration for >8 days

Challenges
  • Cost of goods for API and formulation 

  • Reduced relative activity against P. vivax

  • Single enzyme target; potential for resistance

Status
  • Phase IIa in Peru in patients with P. falciparum or P. vivax malaria completed

  • Controlled Human Malaria Infection Study of combination with OZ439 completed

Next milestone
  • Confirm suitability of new formulation and start Phase I combo safety study

Previously
  • Discovery partnership with University of Texas Southwestern, Washington University and Monash University
MMV Project Director
  • Dr Jörg Möhrle